Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Brain Tumor Pathology
Published in: Brain Tumor Pathology 1/2019

01-01-2019 | Case Report

Identification of a novel KLC1–ROS1 fusion in a case of pediatric low-grade localized glioma

Authors: Yoshiko Nakano, Arata Tomiyama, Takashi Kohno, Akihiko Yoshida, Kai Yamasaki, Tatsuya Ozawa, Kohei Fukuoka, Hiroko Fukushima, Takeshi Inoue, Junichi Hara, Hiroaki Sakamoto, Koichi Ichimura

Published in: Brain Tumor Pathology | Issue 1/2019

Login to get access

Abstract

The proto-oncogene tyrosine-protein kinase ROS1 (ROS1) is a tyrosine kinase that is closely related to anaplastic lymphoma kinase receptor (ALK). We describe a novel KLC1–ROS1 fusion identified in a case of pediatric low-grade glioma. This was detected by RNA sequencing and confirmed by reverse-transcription PCR and fluorescent in situ hybridization. Immunohistochemical staining for ROS1 was positive in the tumor cytoplasm. In vitro analysis demonstrated the oncogenic activity of this fusion, which was suppressed by the ALK/ROS1 inhibitor, crizotinib. Our case and others suggest that various ROS1 fusions might be present in a subset of pediatric gliomas, which could be targeted for therapy.
Appendix
Available only for authorised users
Literature
1.
2.
3.
4.
Verhey KJ, Hammond JW (2009) Traffic control: regulation of kinesin motors. Nat Rev Mol Cell Biol 10:765–777CrossRefPubMed
5.
Togashi Y, Soda M, Sakata S et al (2012) KLC1-ALK: a novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only. PLoS One 7:e31323CrossRefPubMedPubMedCentral
6.
Wang P, Xiao P, Ye Y et al (2017) Rapid response of brain metastasis to crizotinib in a patient with KLC1-ALK fusion and MET gene amplification positive non-small cell lung cancer: a case report. Cancer Biol Med 14:183–186CrossRefPubMedPubMedCentral
7.
Johnson A, Severson E, Gay L et al (2017) Comprehensive genomic profiling of 282 pediatric low- and high-grade gliomas reveals genomic drivers, tumor mutational burden, and hypermutation signatures. Oncologist 22:1478–1490CrossRefPubMedPubMedCentral
8.
Coccé MC, Mardin BR, Bens S et al (2016) Identification of ZCCHC8 as fusion partner of ROS1 in a case of congenital glioblastoma multiforme with a t(6;12)(q21;q24.3). Genes Chromosomes Cancer 55:677–687CrossRefPubMed
9.
Olsen TK, Panagopoulos I, Meling TR et al (2015) Fusion genes with ALK as recurrent partner in ependymoma-like gliomas: a new brain tumor entity? Neuro Oncol 17:1365–1373CrossRefPubMedPubMedCentral
10.
11.
Kiehna EN, Arnush MR, Tamrazi B et al (2017) Novel GOPC(FIG)-ROS1 fusion in a pediatric high-grade glioma survivor. J Neurosurg Pediatr 20:51–55CrossRefPubMed
12.
Rossing M, Yde CW, Sehested A et al (2017) Genomic diagnostics leading to the identification of a TFG-ROS1 fusion in a child with possible atypical meningioma. Cancer Genet 212–213:32–37CrossRefPubMed
13.
Cameron L, Solomon B (2015) New treatment options for ALK-rearranged non-small cell lung cancer. Curr Treat Options Oncol 16:49CrossRefPubMed
14.
Bubendorf L, Büttner R, Al-Dayel F et al (2016) Testing for ROS1 in non-small cell lung cancer: a review with recommendations. Virchows Arch 469:489–503CrossRefPubMedPubMedCentral
15.
Yoshida A, Tsuta K, Wakai S et al (2014) Immunohistochemical detection of ROS1 is useful for identifying ROS1 rearrangements in lung cancers. Mod Pathol 27:711–720CrossRefPubMed
16.
Fujita H, Yoshida A, Taniguchi H et al (2015) Adult-onset inflammatory  myofibroblastic tumour of the stomach with a TFG-ROS1 fusion. Histopathology 66:610–612CrossRefPubMed
17.
Yamamoto H, Yoshida A, Taguchi K et al (2016) ALK, ROS1 and NTRK3 gene rearrangements in inflammatory myofibroblastic tumours. Histopathology 69:72–83CrossRefPubMed
Metadata
Title
Identification of a novel KLC1–ROS1 fusion in a case of pediatric low-grade localized glioma
Authors
Yoshiko Nakano
Arata Tomiyama
Takashi Kohno
Akihiko Yoshida
Kai Yamasaki
Tatsuya Ozawa
Kohei Fukuoka
Hiroko Fukushima
Takeshi Inoue
Junichi Hara
Hiroaki Sakamoto
Koichi Ichimura
Publication date
01-01-2019
Publisher
Springer Singapore
Published in
Brain Tumor Pathology / Issue 1/2019
Print ISSN: 1433-7398
Electronic ISSN: 1861-387X
DOI
https://doi.org/10.1007/s10014-018-0330-3